Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

By H. Grossman, R. Natale, C. Tangen, V. Speights, N. Vogelzang, D. Trump, R. D. White, M. Sarosdy, D. Wood, D. Raghavan and 1 more. New England Journal of Medicine, 2003

2,562 citations recorded by the source corpus.

Subfields: Surgery

View Paper: https://www.semanticscholar.org/paper/51eab49448632d596227169dae3e50a4efa9b961

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Surgery

1. B. V. van Rhijn
2. William Y. Kim

Citations in the corpus

• Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy (2014, positive): “Because NAC pathological complete response is associated with excellent long-term survival (Grossman et al., 2003), aggressive early management of basal MIBCs with NAC offers the best chance for improved survival for patients with this potentially deadly form of this disease.”
• Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. (2017, background): “Nonresponding patients are unlikely to derive clinical benefit, are exposed to substantial toxicity, and experience a delay in definitive local therapy [2,3].”
• Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. (2011, background): “In general, a clinical CR rate of up to 56%, as reported in some series, must be weighed against a staging error of >60% [5,8].”